Track topics on Twitter Track topics that are important to you
The FDA has granted a Breakthrough Therapy designation to the Usona Institute for its trial use of psilocybin in the treatment of major depressive disorder (MDD), with the view of accelerating trials testing its efficacy.
Non-profit research organisation The Usona Institue is examining the antidepressant properties of a single psilocybin dose in treating patients with major depressive disorder.
Original Article: FDA fast-tracks psilocybin treatment for major depressive disorderNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...